Pembrolizumab weight based dosing – A call for policy change-Reference-Cited by-同舟云学术

Pembrolizumab weight based dosing – A call for policy change

Published:2022-02-21 Issue:03 Volume:43 Page:306-310
ISSN:0971-5851
Container-title:Indian Journal of Medical and Paediatric Oncology
language:en
Short-container-title:Indian J Med Paediatr Oncol

Author:

Patel Amol¹^ORCID,Akhade Amol²,Parikh Purvish³,Sharma Atul⁴,Malhotra Hemant⁵^ORCID,Prabhash Kumar⁶,Babu Govind⁷^ORCID,Noronha Vanita⁶,Batra Ullas⁸,Mehta Prashant⁹,Gupta Vineet Govinda¹⁰,Radhakrishnan Venkatraman¹¹,Boya Rakesh Reddy¹²,Biswas Bivas¹³^ORCID

Affiliation:

1. Department of Medicine, Oncology Centre, INHS, ASVINI, Mumbai

2. Department of Medical Oncology, Topiwala National Medical College and Nair Hospital, Mumbai, Maharashtra, India

3. Department of Medical Oncology, Mumbai Oncocare Centers, Mumbai, Maharashtra, India

4. Department of Medical Oncology, AIIMS, New Delhi, India

5. Department of Medical Oncology, Mahatmma Gandhi Medical College Hospital, Jaipur, Rajasthan, India

6. Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

7. Department of Medical Oncology, HCG and St John’s Medical College Hospital, Bengaluru, Karnataka, India

8. Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India

9. Department of Medical Oncology, Asian Institute of Medical Sciences, Faridabad, Haryana, India

10. Department of Medical Oncology, Artemis Hospital, Gurugram, Haryana, India

11. Department of Medical Oncology, Cancer Institute, Chennai, Tamil Nadu, India

12. Department of Medical Oncology, Mahatma Gandhi Cancer Hospital, Vishakhapatnam, Andhra Pradesh, India

13. Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

Publisher

Georg Thieme Verlag KG

Subject

Oncology,Pediatrics, Perinatology and Child Health

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0042-1742651.pdf

Reference24 articles.

1. Pharmacoeconomics;I F Tannock;Ind J Med Paediatr Oncol,2021

2. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors;M Centanni;Clin Pharmacokinet,2019

3. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors;A Patnaik;Clin Cancer Res,2015

4. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer;M Chatterjee;Ann Oncol,2016

5. Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma;M S Chatterjee;CPT Pharmacometrics Syst Pharmacol,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Immune Checkpoint Inhibitors in Various Tumor Types Treated by Low, Per-Weight, and Conventional Doses at a Tertiary Care Center in Mumbai;JCO Global Oncology;2024-01

2. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab;The Lancet Oncology;2022-12